October 18, 2016
San Diego-based Cidara Therapeutics, Inc., a biotechnology company developing novel anti-infectives including immunotherapies, has announced the closing of its previously announced underwritten public offering of 2,475,248 shares of its common stock, plus 277,389 additional shares sold pursuant to the underwriter’s partial exercise of its option to purchase additional shares, each at a price to the public of $10.10 per share. Including this option exercise, the gross proceeds to Cidara from the offering, before deducting underwriting discounts and commissions and other offering expenses, will be approximately $27.8 million. The underwriter has until November 6, 2016 to exercise its option to purchase an additional 93,898 shares of Cidara’s common stock at the public offering price. Latham & Watkins LLP represented the underwriter Cantor Fitzgerald & Co. as the sole book-running manager for the offering with a corporate team led from the firm’s San Diego office by partners Cheston Larson and Michael Sullivan.